Skip to content ↓

Belcher is a 'woman to watch'

Angela Belcher
Caption:
Angela Belcher
Credits:
Photo / Donna Coveney

Professor Angela Belcher is one of 10 New England innovators in fields from biotechnology to software to be honored in Mass High Tech's 2005 Women to Watch program.

"These women will shape the future of their industries while serving as role models for young girls going into science and engineering," said Mass High Tech editor Jim Malone. Each was featured in an article in the Feb. 21 issue of the business and technology newspaper.

Belcher is an associate professor in the Department of Materials Science and Engineering and the Department of Biological Engineering. She is known in part for coaxing biological molecules to self-assemble into nanomaterials with increasingly complex structures. In 2004 Belcher won a MacArthur Fellowship, commonly known as the "genius" grant.

The other Mass High Tech Women to Watch come from Boston University's computer science department, The Digiticians, Target Software Inc., the Charles Stark Draper Laboratory, Authoria Inc., the Boston Cure for Multiple Sclerosis, Genzyme Corp., Botzam Inc., and Novartis Institutes for Biomedical Research.

A version of this article appeared in MIT Tech Talk on March 2, 2005 (download PDF).

Related Links

Related Topics

More MIT News

Rich Nielsen, Volha Charnysh, Kevin Dorst, and Emily Richmond Pollock seated at a table, talking

Building a scholarly community

The SHASS Faculty Fellows Program, administered by the MIT Human Insight Collaborative, is fostering new research projects and creating space for supportive and interdisciplinary discussion.

Read full story

Globular blue and white orbs "examining" single-stranded RNA products and marking them with green checks or red x's

Why are some bacterial genes high in purines?

In certain species of bacteria, the answer lies in shielding RNA transcripts from a quality-control factor called Rho. Understanding the requirements for expressible sequences is critical for expression engineering of therapeutic agents.

Read full story